GSE,Sample_title,Sample_geo_accession,Sample_status,Sample_submission_date,Sample_last_update_date,Sample_type,Sample_channel_count,Sample_source_name_ch1,Sample_organism_ch1,Sample_taxid_ch1,Sample_treatment_protocol_ch1,Sample_growth_protocol_ch1,Sample_molecule_ch1,Sample_extract_protocol_ch1,Sample_data_processing,Sample_platform_id,Sample_contact_name,Sample_contact_email,Sample_contact_laboratory,Sample_contact_department,Sample_contact_institute,Sample_contact_address,Sample_contact_city,Sample_contact_state,Sample_contact_zip/postal_code,Sample_contact_country,Sample_instrument_model,Sample_library_selection,Sample_library_source,Sample_library_strategy,Sample_series_id,Sample_data_row_count,file,file_url,sample_name,file_size,type,Sequencing reads were aligned by Bowtie to the hg19 build of the human genome using the following parameters,Genome_build,Supplementary_files_format_and_content,BioSample,SRA,cell line,cell type,treatment
GSE129802,ATAC-seq_ETV4KO1_DMSO,GSM3722301,Public on Apr 23 2019,Apr 15 2019,Apr 25 2019,SRA,1,Endometrioid adenocarcinoma_1 hr 0.1% DMSO,Homo sapiens,9606,"Inductions involved treating cells with 0.1% DMSO, as a vehicle control, or 10nM E2 (Sigma-Aldrich) for 1 hour.","Ishikawa cells (Sigma-Aldrich) were grown in full media (RPMI-1640 (Gibco), 10% fetal bovine serum (Gibco), and 1% penicillin-streptomycin (Gibco)).  Five days prior to induction, cells were moved to hormone-depleted media with phenol-red free RPMI-1640(Gibco), 10% charcoal-dextran treated fetal bovine serum (Sigma-Aldrich), and 1% penicillin-streptomycin(Gibco).",genomic DNA,"250,000 cells were collected and ATAC assay was performed as described in Buenrostro, et al. 2013., Library was constructed as described in Buenrostro, et al. 2013.",Read counts were calculated using featureCounts from the SubRead package,GPL16791,"Jason,,Gertz",jay.gertz@hci.utah.edu,Gertz,Oncological Sciences,University of Utah,2000 Circle of Hope,Salt Lake City,UT,84112,USA,Illumina HiSeq 2500,other,genomic,ATAC-seq,"GSE129802, GSE129805",0,GSM3722301_ETV4KO1_DMSO_ATAC.bedgraph.gz,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3722nnn/GSM3722301/suppl/GSM3722301_ETV4KO1_DMSO_ATAC.bedgraph.gz,ATAC-seq_ETV4KO1_DMSO,107506947,BEDGRAPH,-m 1  -t –best -q -S -l 32 -e 80 -n 2,hg19,bedgraph,https://www.ncbi.nlm.nih.gov/biosample/SAMN11417699,https://www.ncbi.nlm.nih.gov/sra?term,Ishikawa ETV4 KO clone 1,Endometrioid adenocarcinoma,ETV4 KO
GSE129802,ATAC-seq_ETV4KO1_1hrE2,GSM3722302,Public on Apr 23 2019,Apr 15 2019,Apr 25 2019,SRA,1,Endometrioid adenocarcinoma_1 hr 10nM E2,Homo sapiens,9606,"Inductions involved treating cells with 0.1% DMSO, as a vehicle control, or 10nM E2 (Sigma-Aldrich) for 1 hour.","Ishikawa cells (Sigma-Aldrich) were grown in full media (RPMI-1640 (Gibco), 10% fetal bovine serum (Gibco), and 1% penicillin-streptomycin (Gibco)).  Five days prior to induction, cells were moved to hormone-depleted media with phenol-red free RPMI-1640(Gibco), 10% charcoal-dextran treated fetal bovine serum (Sigma-Aldrich), and 1% penicillin-streptomycin(Gibco).",genomic DNA,"250,000 cells were collected and ATAC assay was performed as described in Buenrostro, et al. 2013., Library was constructed as described in Buenrostro, et al. 2013.",Read counts were calculated using featureCounts from the SubRead package,GPL16791,"Jason,,Gertz",jay.gertz@hci.utah.edu,Gertz,Oncological Sciences,University of Utah,2000 Circle of Hope,Salt Lake City,UT,84112,USA,Illumina HiSeq 2500,other,genomic,ATAC-seq,"GSE129802, GSE129805",0,GSM3722302_ETV4KO1_1hrE2_ATAC.bedgraph.gz,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3722nnn/GSM3722302/suppl/GSM3722302_ETV4KO1_1hrE2_ATAC.bedgraph.gz,ATAC-seq_ETV4KO1_1hrE2,95469891,BEDGRAPH,-m 1  -t –best -q -S -l 32 -e 80 -n 2,hg19,bedgraph,https://www.ncbi.nlm.nih.gov/biosample/SAMN11417704,https://www.ncbi.nlm.nih.gov/sra?term,Ishikawa ETV4 KO clone 1,Endometrioid adenocarcinoma,ETV4 KO
GSE129802,ATAC-seq_ETV4KO2_DMSO,GSM3722303,Public on Apr 23 2019,Apr 15 2019,Apr 25 2019,SRA,1,Endometrioid adenocarcinoma_1 hr 0.1% DMSO,Homo sapiens,9606,"Inductions involved treating cells with 0.1% DMSO, as a vehicle control, or 10nM E2 (Sigma-Aldrich) for 1 hour.","Ishikawa cells (Sigma-Aldrich) were grown in full media (RPMI-1640 (Gibco), 10% fetal bovine serum (Gibco), and 1% penicillin-streptomycin (Gibco)).  Five days prior to induction, cells were moved to hormone-depleted media with phenol-red free RPMI-1640(Gibco), 10% charcoal-dextran treated fetal bovine serum (Sigma-Aldrich), and 1% penicillin-streptomycin(Gibco).",genomic DNA,"250,000 cells were collected and ATAC assay was performed as described in Buenrostro, et al. 2013., Library was constructed as described in Buenrostro, et al. 2013.",Read counts were calculated using featureCounts from the SubRead package,GPL16791,"Jason,,Gertz",jay.gertz@hci.utah.edu,Gertz,Oncological Sciences,University of Utah,2000 Circle of Hope,Salt Lake City,UT,84112,USA,Illumina HiSeq 2500,other,genomic,ATAC-seq,"GSE129802, GSE129805",0,GSM3722303_ETV4KO2_DMSO_ATAC.bedgraph.gz,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3722nnn/GSM3722303/suppl/GSM3722303_ETV4KO2_DMSO_ATAC.bedgraph.gz,ATAC-seq_ETV4KO2_DMSO,85666259,BEDGRAPH,-m 1  -t –best -q -S -l 32 -e 80 -n 2,hg19,bedgraph,https://www.ncbi.nlm.nih.gov/biosample/SAMN11417703,https://www.ncbi.nlm.nih.gov/sra?term,Ishikawa ETV4 KO clone 2,Endometrioid adenocarcinoma,ETV4 KO
GSE129802,ATAC-seq_ETV4KO2_1hrE2,GSM3722304,Public on Apr 23 2019,Apr 15 2019,Apr 25 2019,SRA,1,Endometrioid adenocarcinoma_1 hr 10nM E2,Homo sapiens,9606,"Inductions involved treating cells with 0.1% DMSO, as a vehicle control, or 10nM E2 (Sigma-Aldrich) for 1 hour.","Ishikawa cells (Sigma-Aldrich) were grown in full media (RPMI-1640 (Gibco), 10% fetal bovine serum (Gibco), and 1% penicillin-streptomycin (Gibco)).  Five days prior to induction, cells were moved to hormone-depleted media with phenol-red free RPMI-1640(Gibco), 10% charcoal-dextran treated fetal bovine serum (Sigma-Aldrich), and 1% penicillin-streptomycin(Gibco).",genomic DNA,"250,000 cells were collected and ATAC assay was performed as described in Buenrostro, et al. 2013., Library was constructed as described in Buenrostro, et al. 2013.",Read counts were calculated using featureCounts from the SubRead package,GPL16791,"Jason,,Gertz",jay.gertz@hci.utah.edu,Gertz,Oncological Sciences,University of Utah,2000 Circle of Hope,Salt Lake City,UT,84112,USA,Illumina HiSeq 2500,other,genomic,ATAC-seq,"GSE129802, GSE129805",0,GSM3722304_ETV4KO2_1hrE2_ATAC.bedgraph.gz,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3722nnn/GSM3722304/suppl/GSM3722304_ETV4KO2_1hrE2_ATAC.bedgraph.gz,ATAC-seq_ETV4KO2_1hrE2,59300815,BEDGRAPH,-m 1  -t –best -q -S -l 32 -e 80 -n 2,hg19,bedgraph,https://www.ncbi.nlm.nih.gov/biosample/SAMN11417702,https://www.ncbi.nlm.nih.gov/sra?term,Ishikawa ETV4 KO clone 2,Endometrioid adenocarcinoma,ETV4 KO
GSE129802,ATAC-seq_WTIshikawa_DMSO,GSM3722305,Public on Apr 23 2019,Apr 15 2019,Apr 25 2019,SRA,1,Endometrioid adenocarcinoma_1 hr 0.1% DMSO,Homo sapiens,9606,"Inductions involved treating cells with 0.1% DMSO, as a vehicle control, or 10nM E2 (Sigma-Aldrich) for 1 hour.","Ishikawa cells (Sigma-Aldrich) were grown in full media (RPMI-1640 (Gibco), 10% fetal bovine serum (Gibco), and 1% penicillin-streptomycin (Gibco)).  Five days prior to induction, cells were moved to hormone-depleted media with phenol-red free RPMI-1640(Gibco), 10% charcoal-dextran treated fetal bovine serum (Sigma-Aldrich), and 1% penicillin-streptomycin(Gibco).",genomic DNA,"250,000 cells were collected and ATAC assay was performed as described in Buenrostro, et al. 2013., Library was constructed as described in Buenrostro, et al. 2013.",Read counts were calculated using featureCounts from the SubRead package,GPL16791,"Jason,,Gertz",jay.gertz@hci.utah.edu,Gertz,Oncological Sciences,University of Utah,2000 Circle of Hope,Salt Lake City,UT,84112,USA,Illumina HiSeq 2500,other,genomic,ATAC-seq,"GSE129802, GSE129805",0,GSM3722305_WTIshikawa_DMSO_ATAC.bedgraph.gz,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3722nnn/GSM3722305/suppl/GSM3722305_WTIshikawa_DMSO_ATAC.bedgraph.gz,ATAC-seq_WTIshikawa_DMSO,82199045,BEDGRAPH,-m 1  -t –best -q -S -l 32 -e 80 -n 2,hg19,bedgraph,https://www.ncbi.nlm.nih.gov/biosample/SAMN11417701,https://www.ncbi.nlm.nih.gov/sra?term,Ishikawa,Endometrioid adenocarcinoma,WT
GSE129802,ATAC-seq_WTIshikawa_1hrE2,GSM3722306,Public on Apr 23 2019,Apr 15 2019,Apr 25 2019,SRA,1,Endometrioid adenocarcinoma_1 hr 10nM E2,Homo sapiens,9606,"Inductions involved treating cells with 0.1% DMSO, as a vehicle control, or 10nM E2 (Sigma-Aldrich) for 1 hour.","Ishikawa cells (Sigma-Aldrich) were grown in full media (RPMI-1640 (Gibco), 10% fetal bovine serum (Gibco), and 1% penicillin-streptomycin (Gibco)).  Five days prior to induction, cells were moved to hormone-depleted media with phenol-red free RPMI-1640(Gibco), 10% charcoal-dextran treated fetal bovine serum (Sigma-Aldrich), and 1% penicillin-streptomycin(Gibco).",genomic DNA,"250,000 cells were collected and ATAC assay was performed as described in Buenrostro, et al. 2013., Library was constructed as described in Buenrostro, et al. 2013.",Read counts were calculated using featureCounts from the SubRead package,GPL16791,"Jason,,Gertz",jay.gertz@hci.utah.edu,Gertz,Oncological Sciences,University of Utah,2000 Circle of Hope,Salt Lake City,UT,84112,USA,Illumina HiSeq 2500,other,genomic,ATAC-seq,"GSE129802, GSE129805",0,GSM3722306_WTIshikawa_1hrE2_ATAC.bedgraph.gz,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3722nnn/GSM3722306/suppl/GSM3722306_WTIshikawa_1hrE2_ATAC.bedgraph.gz,ATAC-seq_WTIshikawa_1hrE2,81542861,BEDGRAPH,-m 1  -t –best -q -S -l 32 -e 80 -n 2,hg19,bedgraph,https://www.ncbi.nlm.nih.gov/biosample/SAMN11417700,https://www.ncbi.nlm.nih.gov/sra?term,Ishikawa,Endometrioid adenocarcinoma,WT
